RxDoctor Payments Data

Jason Andersen, DO

Child & Adolescent Psychiatry · Orem, UTNPI 1932293727

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 53.9% of the total. Reporting peaked in 2020 at $170 and has fallen 89.7% since, to $18 in 2023.

$483in general payments, 2019–2025

Across 9 payments — averaging $53.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260
  • Indivior Inc.$122
  • Otsuka America Pharmaceutical, Inc.$76
  • Sunovion Pharmaceuticals Inc.$25
$1,143,672in research payments, 2019–2025

Across 117 payments — averaging $9774.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$482K
  • Supernus Pharmaceuticals, Inc.$372K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$163K
  • H. Lundbeck A S$41K
  • Bristol Myers Squibb$20K
  • Institut DE Recherches Internationales Servier$19K
  • plus $47K from 6 others

What the payments were for

  • Food & beverage$483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$483 in reported general payments places this provider in the 80th percentile of 29 child & adolescent psychiatry providers in Utah.

See all child & adolescent psychiatry providers in Utah

Medicare billing

Part B allowed, 2024
$14,915
Medicare patients
19
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other child & adolescent psychiatry in Orem

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →